Phenotypes associated with this allele

• Allele Symbol: Actb^{tm4(cre/ERT2)Npa}
• Allele Name: targeted mutation 4, Novartis Pharma AG
• Allele ID: MGI:5514361
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Actb^tm4(cre/ERT2)Npa/Actb^+ Sgpl1^tm1.1Npa/Sgpl1^tm1.1Npa	involves: BALB/cJ * C57BL/6	MGI:5515215

Genotype
MGI:5515215

cn1

• Allelic Composition: Actb^{tm4(cre/ERT2)Npa}/Actb⁺; Sgpl1^tm1.1Npa/Sgpl1^tm1.1Npa
• Genetic Background: involves: BALB/cJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:199525 )

N • with tamoxifen treatment mice show normal survival up to 6 months of observation

growth/size/body

growth/size/body region phenotype ( J:199525 )

N • after tamoxifen treatment mice show normal weight gain up to 6 months of observation

hematopoietic system

increased thymocyte number ( J:199525 )

• thymocytes are enriched in mature single-positive T cells

decreased follicular B cell number ( J:199525 )

• with tamoxifen treatment total numbers are decreased significantly, with no significant change in germinal center B cells

decreased marginal zone B cell number ( J:199525 )

• with tamoxifen treatment total numbers are decreased significantly, with no significant change in germinal center B cells

abnormal regulatory T cell number ( J:199525 )

• with tamoxifen treatment numbers of CD4+Foxp3+ T cells are reduced 3-4 fold in spleen and increased more than 4-fold in lymph nodes with tamoxifen treatment

decreased single-positive T cell number ( J:199525 )

• mice treated with tamoxifen daily for 5 days have decreases in CD4- and CD8-positive T cells by up to 85% two weeks later, lasting for at least 6 months; CD19-positive B cell numbers are unchanged

• at 8 weeks after tamoxifen treatment, splenic populations of CD4- and CD8-positive T cells are sharply reduced

spleen hypoplasia ( J:199525 )

• at 8 weeks after tamoxifen treatment splenic cellularity sharply decreased with significant reductions in CD- and CD8-positive T cells and subpopulations of B cells

immune system

increased thymocyte number ( J:199525 )

• thymocytes are enriched in mature single-positive T cells

decreased follicular B cell number ( J:199525 )

• with tamoxifen treatment total numbers are decreased significantly, with no significant change in germinal center B cells

decreased marginal zone B cell number ( J:199525 )

• with tamoxifen treatment total numbers are decreased significantly, with no significant change in germinal center B cells

abnormal regulatory T cell number ( J:199525 )

• with tamoxifen treatment numbers of CD4+Foxp3+ T cells are reduced 3-4 fold in spleen and increased more than 4-fold in lymph nodes with tamoxifen treatment

decreased single-positive T cell number ( J:199525 )

• mice treated with tamoxifen daily for 5 days have decreases in CD4- and CD8-positive T cells by up to 85% two weeks later, lasting for at least 6 months; CD19-positive B cell numbers are unchanged

• at 8 weeks after tamoxifen treatment, splenic populations of CD4- and CD8-positive T cells are sharply reduced

spleen hypoplasia ( J:199525 )

• at 8 weeks after tamoxifen treatment splenic cellularity sharply decreased with significant reductions in CD- and CD8-positive T cells and subpopulations of B cells

abnormal lymph node morphology ( J:199525 )

• with tamoxifen treatment lymph node cell numbers are significantly increased with an increase in CD4- and CD8-positive T cells and total B cell numbers (except germinal center B cells

abnormal type IV hypersensitivity reaction ( J:199525 )

• tamoxifen treated mice are protected from delayed-type hypersensitivity reaction induced by localized challenge with sheep red blood cells

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:199525 )

• tamoxifen treated mice are almost completely protected from MOG-induced EAE

homeostasis/metabolism

abnormal lipid homeostasis ( J:199525 )

• 2 weeks after induction of cre, levels of S1P (Sgpl1 substrate) are increased 4-fold (heart) to 100-fold (spleen/lymph nodes) with no significant increase in the brain or spinal cord; blood concentrations are elevate only 1.6-fold

• ceramide (S1P precursor) is not significantly elevated with Sph (S1P precursor) increased 16-fold

• increase of sphingolipid metabolites is much less pronounce than in constitutive Sgpl1 knockouts

endocrine/exocrine glands

increased thymocyte number ( J:199525 )

• thymocytes are enriched in mature single-positive T cells